Cigna (CI) is trading lower as investors reprice the earnings-risk profile of its Evernorth unit, which includes Express Scripts, amid a transition away from traditional rebate economics and heightened regulatory attention on PBMs. The overhang intensified after Express Scripts reached a settlement with federal antitrust enforcers over insulin pricing practices, keeping scrutiny on how PBMs earn profits and what concessions may mean for future economics.

While Cigna has a large health benefits business, Evernorth is a major profit engine, and small changes in spread, rebate, and pricing mechanics can have outsized impacts on consolidated margins and valuation. Investors are increasingly sensitive to signals that the industry’s traditional rebate-heavy model could face structural compression as reforms, consent orders, and client pressure accelerate point-of-sale pass-through and cost-plus reimbursement approaches.

Key near-term catalysts include any additional details on implementation timelines and economics tied to the FTC settlement obligations, client adoption trends for newer PBM pricing models, and updated commentary on 2026 margin cadence. Investors will also watch for broader PBM-policy developments and managed-care cost trend signals that could either stabilize sentiment or deepen concerns about profit compression.